Hims & Hers Health, Inc.
NYSE:HIMSMedical - Equipment & Services
+$1.11 today
- Market cap
- $3.85B
- Beta
- 2.40
- P/E (TTM)
- -569.3
- EPS (TTM)
- -$0.06
Volume 9.53M
Average 26.18M
HIMS EBITDA Margin
EBITDA as a percentage of revenue.
Hims & Hers Health, Inc.NYSE: HIMS
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin narrows to -7.4%
EBITDA Margin was -7.4% in Q3 FY2026, down 12.4 pp from a year earlier. On a trailing-twelve-month basis it was -6.0%, down 13.7 pp year over year. Over 3 fiscal years it widened by 18.7 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 9.9% for the fiscal year ending Dec 2026, up from 7.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -7.4%+1.0 pp QoQ
- Last fiscal yearDec 2025
- 7.6%+1.6 pp YoY
- LTMSep 2026
- -6.0%-13.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.4 pp | +4.2 pp | +16.6 pp |
| 1 year | +1.6 pp | +2.3 pp | +0.8 pp |
| 3 years | +18.7 pp | +3.0 pp | -15.7 pp |
| 5 years | -0.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 7.6%
- Year-over-year change
- +1.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.6% | +1.6pp |
| FY2024 | 2024-12-31 | 6.0% | +7.4pp |
| FY2023 | 2023-12-31 | -1.4% | +9.7pp |
| FY2022 | 2022-12-31 | -11.1% | +28.2pp |
| FY2021 | 2021-12-31 | -39.3% | — |
EBITDA Margin vs competitors
How HIMS compares with its peers on the latest reported figures
- HIMS's LTM Sep 2026 EBITDA Margin of -6.0% is the 8th highest of the 10 companies compared; the peer median is -0.0%.
- Its year-over-year change of -13.7 pp is the 8th highest of 10, against a peer median of -4.7 pp.
- Over three fiscal years its change of +18.7 pp compares with a peer median of -4.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 21.0% | +1.4 pp | -2.5 pp | |
| LTM Jun 2026 | 12.6% | -3.1 pp | -4.9 pp | |
| LTM Sep 2026 | 12.2% | +9.3 pp | -4.1 pp | |
| LTM Mar 2026 | 5.3% | -6.8 pp | -4.8 pp | |
| LTM Sep 2026 | -0.0% | -4.7 pp | -16.9 pp | |
| LTM Mar 2026 | -1.9% | -3.3 pp | +31.6 pp | |
| LTM Mar 2026 | -2.4% | -4.9 pp | +12.0 pp | |
| LTM Sep 2026 | -6.0% | -13.7 pp | +18.7 pp | |
| LTM Feb 2026 | -17.7% | -31.6 pp | -54.6 pp | |
| LTM Jun 2026 | -25.2% | -39.4 pp | -26.7 pp | |
| Peer median (excluding HIMS) | -0.0% | -4.7 pp | -4.8 pp | |
Competitors are the stored peer set for HIMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 271.88M | 526.92M | 872M | 1.48B | 2.35B |
| Cost of Revenue | 67.38M | 118.19M | 157.05M | 303.38M | 614.26M |
| Gross Profit | 204.49M | 408.72M | 714.95M | 1.17B | 1.73B |
| Gross Margin | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% |
| Research & Development | 22.38M | 29.24M | 48.23M | 78.82M | 149.3M |
| Selling, General & Admin | 249.56M | 370.78M | 576.32M | 846.61M | 1.19B |
| Operating Expenses | 319.54M | 477.42M | 744.4M | 1.11B | 1.63B |
| Depreciation & Amortization | 4.08M | 7.47M | 9.52M | 17.09M | 54.5M |
| EBITDA | (106.72M) | (58.24M) | (12.06M) | 88.8M | 178.43M |
| EBITDA Margin | -39.3% | -11.1% | -1.4% | 6.0% | 7.6% |
| Operating Income | (115.04M) | (68.7M) | (29.45M) | 61.9M | 105.61M |
| Operating Margin | -42.3% | -13.0% | -3.4% | 4.2% | 4.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.25M | 2.99M | 7.88M | 9.81M | 18.31M |
| Income Before Tax | (110.8M) | (65.71M) | (21.57M) | 71.71M | 123.92M |
| Pre-Tax Margin | -40.8% | -12.5% | -2.5% | 4.9% | 5.3% |
| Income Tax Expense | (3.14M) | (31K) | 1.98M | (54.33M) | (4.44M) |
| Net Income | (107.66M) | (65.68M) | (23.55M) | 126.04M | 128.37M |
| Net Margin | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% |
| EPS (Basic) | (0.58) | (0.32) | (0.11) | 0.58 | 0.57 |
| EPS (Diluted) | (0.58) | (0.32) | (0.11) | 0.53 | 0.51 |
| Weighted Avg Shares | 186.78M | 204.52M | 209.34M | 215.94M | 224.96M |
| Weighted Avg Shares (Diluted) | 186.78M | 204.52M | 209.34M | 236.81M | 258.23M |
Hims & Hers Health, Inc.
NYSE:HIMS
Intrinsic Alpha fair value
Locked
Current Price
$17.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.